Literature DB >> 23831274

How the microenvironment wires the natural history of chronic lymphocytic leukemia.

Federico Caligaris-Cappio1, Maria T S Bertilaccio2, Cristina Scielzo2.   

Abstract

The investigation on the mechanisms that govern the development and progression of cancer is constantly swaying between "seed" and "soil". Chronic lymphocytic leukemia (CLL) makes no exception. Its natural history, including response to treatment and drug resistance, is determined both by causal and influential genes and by the relationships that leukemic cells entertain with their supportive microenvironments. Therefore dissecting the role of microenvironment may provide new strategies of diagnosis and treatment. CLL, though phenotypically homogeneous, is clinically heterogeneous and despite major therapeutic advances remains incurable. Conceivably the host of new non-genotoxic drugs that operate at the forefront between tumor cells and their milieu will modify the present therapeutic perspective by re-shaping the tumor cell/microenvironment cross talk.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chronic lymphocytic leukemia; Cytoskeleton; Microenviroment; Mouse models

Mesh:

Year:  2013        PMID: 23831274     DOI: 10.1016/j.semcancer.2013.06.010

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  39 in total

1.  [Chronic lymphocytic leukemia : treatment concepts in transition].

Authors:  B Eichhorst; M Hallek
Journal:  Internist (Berl)       Date:  2015-04       Impact factor: 0.743

2.  Activation of the PI3K/AKT pathway by microRNA-22 results in CLL B-cell proliferation.

Authors:  F Palacios; C Abreu; D Prieto; P Morande; S Ruiz; T Fernández-Calero; H Naya; G Libisch; C Robello; A I Landoni; R Gabus; G Dighiero; P Oppezzo
Journal:  Leukemia       Date:  2014-05-14       Impact factor: 11.528

3.  p66Shc deficiency sets the scene for clinically aggressive chronic lymphocytic leukemia.

Authors:  Richard Rosenquist
Journal:  Haematologica       Date:  2019-10       Impact factor: 9.941

4.  The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia.

Authors:  Sarah E M Herman; Arnau Montraveta; Carsten U Niemann; Helena Mora-Jensen; Michael Gulrajani; Fanny Krantz; Rose Mantel; Lisa L Smith; Fabienne McClanahan; Bonnie K Harrington; Dolors Colomer; Todd Covey; John C Byrd; Raquel Izumi; Allard Kaptein; Roger Ulrich; Amy J Johnson; Brian J Lannutti; Adrian Wiestner; Jennifer A Woyach
Journal:  Clin Cancer Res       Date:  2016-11-30       Impact factor: 12.531

5.  Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial.

Authors:  Mohammed Z H Farooqui; Janet Valdez; Sabrina Martyr; Georg Aue; Nakhle Saba; Carsten U Niemann; Sarah E M Herman; Xin Tian; Gerald Marti; Susan Soto; Thomas E Hughes; Jade Jones; Andrew Lipsky; Stefania Pittaluga; Maryalice Stetler-Stevenson; Constance Yuan; Yuh Shan Lee; Lone B Pedersen; Christian H Geisler; Katherine R Calvo; Diane C Arthur; Irina Maric; Richard Childs; Neal S Young; Adrian Wiestner
Journal:  Lancet Oncol       Date:  2014-12-31       Impact factor: 41.316

6.  The splenic marginal zone shapes the phenotype of leukemia B cells and facilitates their niche-specific retention and survival.

Authors:  Vanessa Stache; Lydia Verlaat; Marcel Gätjen; Kristina Heinig; Jörg Westermann; Armin Rehm; Uta E Höpken
Journal:  Oncoimmunology       Date:  2017-05-02       Impact factor: 8.110

7.  From a 2DE-gel spot to protein function: lesson learned from HS1 in chronic lymphocytic leukemia.

Authors:  Benedetta Apollonio; Maria Teresa Sabrina Bertilaccio; Umberto Restuccia; Pamela Ranghetti; Federica Barbaglio; Paolo Ghia; Federico Caligaris-Cappio; Cristina Scielzo
Journal:  J Vis Exp       Date:  2014-10-19       Impact factor: 1.355

Review 8.  Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment.

Authors:  Elisa Ten Hacken; Jan A Burger
Journal:  Biochim Biophys Acta       Date:  2015-07-17

9.  Silenced B-cell receptor response to autoantigen in a poor-prognostic subset of chronic lymphocytic leukemia.

Authors:  Ann-Charlotte Bergh; Chamilly Evaldsson; Lone Bredo Pedersen; Christian Geisler; Kostas Stamatopoulos; Richard Rosenquist; Anders Rosén
Journal:  Haematologica       Date:  2014-08-01       Impact factor: 9.941

Review 10.  Preclinical modeling of novel therapeutics in chronic lymphocytic leukemia: the tools of the trade.

Authors:  Sarah E M Herman; Adrian Wiestner
Journal:  Semin Oncol       Date:  2016-02-08       Impact factor: 4.929

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.